• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

End of year Layoffs









sorry Charlie - every division with be hit. Especially reps with tenure, of certain age. Those making, high salaries and bonus regardless of company or products. Time to clean up numbers. They say things will not change in especially high growth divisions because they want business as usual until deal closes. Don’t be foolish

“Don’t be foolish.” Fuck you. Like you know a fucking thing. Eat a pile of shit dude.
 








Tension anyone??? Unfortunately I do know- just a roll of the dice. Don’t say I didn’t warn you . . .

Ya don’t know shit, dude. Ya don’t know shit. There is not a rep, dm, vp anyone else that has any real knowledge of what is going to happen. The people making the decisions aren’t asking or telling anyone outside of the room what’s going or what going to happen until the day the calls are made.
 




Ya don’t know shit, dude. Ya don’t know shit. There is not a rep, dm, vp anyone else that has any real knowledge of what is going to happen. The people making the decisions aren’t asking or telling anyone outside of the room what’s going or what going to happen until the day the calls are made.

Outside observer here but Allergan reps are gonna be part of a bloodbath. Y’all dont have your head in the sand. Start looking for jobs now. They’re very very difficult to find and then get hired for
 












i can’t stop laughing after talking to a legacy AGN rep- she thinks she gonna be alright, haha. Although her numbers look good right now- ooops. She’s prime for eliminating. See ya... this fall before acquisition- they don’t wanna pay ya and no trip sista.
 
















Unfortunately Eye Care is the definition of low growth/no growth with nothing exciting or meaningful to look forward to. Record of launch failures and nothing exciting on horizon doesn’t bode well for the group
 




Unfortunately Eye Care is the definition of low growth/no growth with nothing exciting or meaningful to look forward to. Record of launch failures and nothing exciting on horizon doesn’t bode well for the group
What you see and what you hear depends a great deal on where you are standing. Eye Care has a promising future!